Neuropace Cash Conversion Cycle from 2010 to 2026
| NPCE Stock | USD 15.28 0.02 0.13% |
Cash Conversion Cycle | First Reported 2010-12-31 | Previous Quarter 277.71 | Current Value 294.1 | Quarterly Volatility 20.57784031 |
Check Neuropace financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neuropace's main balance sheet or income statement drivers, such as Interest Income of 3.7 M, Depreciation And Amortization of 1.4 M or Interest Expense of 7.1 M, as well as many indicators such as Price To Sales Ratio of 4.93, Dividend Yield of 0.0 or PTB Ratio of 38.44. Neuropace financial statements analysis is a perfect complement when working with Neuropace Valuation or Volatility modules.
Neuropace | Cash Conversion Cycle | Build AI portfolio with Neuropace Stock |
Analyzing Neuropace's Cash Conversion Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Cash Conversion Cycle has evolved provides context for assessing Neuropace's current valuation and future prospects.
Latest Neuropace's Cash Conversion Cycle Growth Pattern
Below is the plot of the Cash Conversion Cycle of Neuropace over the last few years. It is Neuropace's Cash Conversion Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neuropace's overall financial position and show how it may be relating to other accounts over time.
| Cash Conversion Cycle | 10 Years Trend |
|
Cash Conversion Cycle |
| Timeline |
Neuropace Cash Conversion Cycle Regression Statistics
| Arithmetic Mean | 288.12 | |
| Geometric Mean | 287.39 | |
| Coefficient Of Variation | 7.14 | |
| Mean Deviation | 17.56 | |
| Median | 302.45 | |
| Standard Deviation | 20.58 | |
| Sample Variance | 423.45 | |
| Range | 60.9548 | |
| R-Value | (0.69) | |
| Mean Square Error | 235.71 | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (2.82) | |
| Total Sum of Squares | 6,775 |
Neuropace Cash Conversion Cycle History
About Neuropace Financial Statements
Neuropace stakeholders use historical fundamental indicators, such as Neuropace's Cash Conversion Cycle, to determine how well the company is positioned to perform in the future. Although Neuropace investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neuropace's assets and liabilities are reflected in the revenues and expenses on Neuropace's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neuropace. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Cash Conversion Cycle | 277.71 | 294.10 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:Check out the analysis of Neuropace Correlation against competitors. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Will Health Care Equipment & Supplies sector continue expanding? Could Neuropace diversify its offerings? Factors like these will boost the valuation of Neuropace. Anticipated expansion of Neuropace directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuropace data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.75) | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets | Return On Equity |
Understanding Neuropace requires distinguishing between market price and book value, where the latter reflects Neuropace's accounting equity. The concept of intrinsic value - what Neuropace's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neuropace's price substantially above or below its fundamental value.
It's important to distinguish between Neuropace's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neuropace should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neuropace's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.